Stem Cell Technologies and Applications: World Industry and Market Outlook 2015-2025
LONDON, January 20, 2015 /PRNewswire/ --
Report Details
Stem cells, an expanding market with vast potential - explore developments and commercial prospects
What does the future hold for that cellular technology? What progress and sales are possible? There avoid struggles to gain business data. Instead find the best places for expanding revenues, also understanding trends, technologies, therapies and opportunities.
Visiongain's new investigation gives you revenue forecasts to 2025 for the world stem cells market, submarkets and leading products. Avoid missing out. There see what's happening for those cell-based technologies and uses, discovering the most lucrative applications.
See what gains are possible. Please read on, then, to explore that industry and discover what its future market could be worth.
Forecasts and other analyses showing opportunities in those cellular technologies
Besides revenue forecasting to 2025, our analyses show recent results, growth rates and market shares. There you find original analysis. Also that work lets you assess research and development. And there gain 55 tables, 38 charts and six interviews with organisations.
Now make your searching for data on stem cells easier. Also save time. And benefit your insight and authority. Our study's purpose is to help in research, analysis and decisions, helping you discover where developments and money lie, staying ahead in knowledge.
And the following sections highlight what's in that technology, industry and market survey.
To see a report overview please email Sara Peerun on [email protected]
Prospects for the overall world market and segments - what's possible?
What're the secrets of that industry's progress? Along with our prediction of the overall world market value for stem cells, our work shows you individual revenue forecasting of five submarkets to 2025 at world level, with discussions:
• Cancer (oncology)
• Central nervous system (CNS) disorders
• Cardiovascular diseases
• Other medical treatments
• Non-therapeutic uses.
Which segment can achieve highest sales? Which has fastest predicted growth? See how and why those commercial uses in healthcare can develop, prosper and gain in importance.
For developers, producers and sellers, assess how those tools, systems and applications earn money. And gauge their potential success from this decade onwards.
Products - discover sales forecasting of leading agents
Our study also shows you individual revenue predictions to 2025 for six top brands:
• Prochymal (Mesoblast)
• Hearticellgram-AMI (Pharmicell)
• CardioRel (Reliance Life Sciences)
• Osteocel Plus (NuVasive)
• Trinity Elite and Evolution (Orthofix)
• Cartistem (Medipost).
There you discover prospects for established and emerging technology and medicines. That market will grow through the approval and launch of many products from this decade.
Our study explains, looking ahead, discussing issues to help your work.
Developments, challenges and opportunities affecting researchers, producers and users
Our investigation lets you assess trends, R&D and outlooks for stem cell technology. There you find discussions of forces, progress and potential:
• Developments in the US, Japan, Europe, South Korea, China, India and Israel, with regulations, achievements, regional prominence and outlooks
• Activities of Mesoblast, Pharmicell, NuVasive, Orthofix, Medipost, Advanced Cell Technology, Athersys, Novartis, GSK and other organisations, private and public
• Approvals of therapies and other products to expand and advance that industry
• Japan's accelerated marketing authorisation for promising treatments
• Regenerative medicine and uses in diabetes, liver degeneration, Crohn's disease, diabetes, rheumatoid arthritis and other medical conditions.
That study discusses other influences, including these:
• Embryonic stem cells (ESCs), induced pluripotent adult (IPSCs) and parthenogenetic cells
• Autologous versus allogeneic cellular agents - possibility for universal products
• Haematopoietic stem cell transplantation (HSCT)
• Uses for umbilical cord blood and related technologies, including cellular banking
• Treatments for orphan diseases and difficult-to-cure disorders
• Agents for osteogenesis and treating autoimmune conditions
• Applications in cell-based assays, diagnostics and drug development.
There you explore political, economic, social and technological questions, assessing advances and prospects. You also gain regulatory insights. That way you investigate what helps and restrains those developers, producers and marketers.
Discover there what the past, present and future hold.
To see a report overview please email Sara Peerun on [email protected]
Stem cells - what's next, and world 2018 market value?
From 2014 those technologies, services and products hold great potential for advances, investments and sales. Our work predicts the overall market for stem cells will reach $12bn in 2018, achieving high revenue growth from 2015 to 2025.
That study's author said: "Therapies in myocardial infarction, heart failure and other prominent diseases have reached phase III trials, suggesting the stem cells market will achieve rapid growth during the middle of our forecast period.
"Clinical-stage companies there focus on CNS disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease. They also tackle ophthalmic conditions, including age-related macular degeneration (AMD)."
Prospects for those medical systems and tools are strong, and from 2015 there will arise many opportunities. Our work shows you the possibilities, helping you stay ahead.
Stem Cell Technologies and Applications: World Industry and Market Outlook 2015-2025 shows information found nowhere else
In particular you gain these analyses to help your research, assessments and decisions:
• Overall world revenue to 2025 - see the results and sales potential of that industry
• Five submarkets' revenues to 2025 - investigate segments at world level, finding the most lucrative applications
• Six product revenues to 2025 - discover sales predictions for top medical agents, seeing how they can succeed, including what helps and limits their performance
• R&D on stem cells - investigate progress, finding technological, clinical and commercial outlooks, including products expected in the next 10 years
• Activities of established, rising and emerging companies - hear about firms' capabilities, portfolios, advances and prospects
• Interviews with six organisations - explore views to help your work, getting feel for that sector and its participants
• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and gain advantages.
Potential for stem cells - discover now what's possible worldwide from 2015
There you receive business intelligence found only in our work, discovering where money, progress and opportunities lie. That way you can benefit your influence and reputation for insight.
With our new study you're less likely to miss opportunity or fall behind. Instead stay ahead for knowledge. You explore trends, R&D and sales predications, with discussions. So please get our report here now.
To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100
Companies Listed on this report
3-D Matrix
Adistem
Advanced Cell Technology
Ageless Regenerative Institute
Aldagen
Alder Biopharmaceuticals
Alkems
AllCells
Allergan
Alliancells Bioscience Corporation (subsidiary of Zhongyuan Union Stem Cell Bio-engineering)
AlloCure
Allosource
ALS Association
American Academy of Pediatrics (AAP)
American Board of Cosmetic Surgery
American Board of Otolaryngology/head and Neck Surgery
American College of Surgeons
American CryoStem
American Society of Blood and Marrow Transplantation
Americas Committee for Treatment and Research in Multiple Sclerosis
Americord
Amgen
Amorcyte
AngioCrine Bioscience
Angiotech Pharmaceuticals
Anterogen (subsidiary of Bukwang Pharm Co Ltd)
Antria
apceth
Aristotle University of Thessaloniki
Arteriocyte
Asterias Biotherapeutics (subsidiary of BioTime)
Athersys
Autogenesis
Axiogenesis
Baxter International
BaYi Brain Hospital (China)
Beike Biotechnology
Berkshire Hathaway
Beth Israel Deaconess Medical Center
BioCardia
BioE
BioEden
Biogen Idec
Biogenea-Cellgenea
Bioheart
Biologic Therapies
Biomatrica
Biomet
BioRestorative Therapies
Biotec Services International
BioTime
BioTime Asia (subsidiary of BioTime)
Blackstone Medical (acquired by Orthofix)
bluebird bio
Boston Children's Hospital
BrainStorm Cell Therapeutics
Bukwang Pharm Co Ltd
California Institute of Regenerative Medicine (CIRM)
California Institute of Technology (Caltech)
Calimmune
Cancer Research UK / Cancer Research Technology
Capricor
Cardio3 BioSciences
Cardiogenesis
Carolinas Cord Blood Bank
Casey Eye Institute, Oregon Health and Science University
Cedars-Sinai Heart Institute
Celgene
Celgene Cellular Therapeutics (formerly Anthrogenesis; subsidiary of Celgene)
Cell Cure Neurosciences (subsidiary of BioTime)
Cell Surgical Network
Cell Targeting (assets acquired by BioTime)
Cell Therapy Limited
Cellartis (subsidiary of Takara Bio)
CellCentric
Cellectis
Cellerant Therapeutics
Cellerix (merged with TiGenix)
Cellonis Biotechnologies
CellProthera
CellSeed
Cellular Biomedicine Group
Cellular Dynamics International (CDI)
Center for International Blood and Marrow Transplant Research (CIBMTR)
Centers for Medicare & Medicaid Services (CMS)
Cephalon (part of Teva)
Cesca Therapeutics
CHA Biotech
Cha General Hospital (Seoul, South Korea)
Chicago Medical School
China Cord Blood Corporation
Chinese Academy of Sciences
Cipla
CJ CheilJedang
Cleveland Biolabs
ClinImmune Labs
Cognate BioServices
Consortium of Multiple Sclerosis Centers
Cook General BioTechnology
Cord Blood America
Cord Blood Registry Systems
Cordlife Group
CoreStem
CRISPR Therapeutics
Cryo-Cell International
CryoCord
Cryonix CJSC
Cryo-Save
CryoSite
CXR Biosciences
Cynata Therapeutics (formerly Eco Quest Ltd)
Cytori Therapeutics
Dendreon
Department of Biotechnology (India)
Dong-A Pharmaceuticals Co. (South Korea)
Duke University
Eli Lilly
EpiStem
ES Cell International (subsidiary of BioTime)
ESI BIO (subsidiary of BioTime)
European Group for Blood and Marrow Transplantation (EBMT)
European Haematology Association
European Medicines Agency (EMA)
Fate Therapeutics
FDS Pharma
Fondazione Centro San Raffaele
Fondazione Telethon
Forbion Capital Partners
Forticell Bioscience
Gamida Cell
Gemabank (Human Stem Cells Institute cord blood bank)
Genetrix Group
Genomics Institute, Novartis Research Foundation
Genzyme (part of Sanofi)
Geron Corporation
Gilead Sciences
GlobalStem
Globocan
GMP Unlimited
Grey Innovation
GSK
Hadassah Medical Center
Harvard Apparatus Regenerative Technology
Harvard Business School
Harvard Stem Cell Institute
Harvard University
Health Canada
Human Fertilisation and Embryology Authority (HFEA) (UK)
Human Stem Cells Institute (Russia)
ImmunoCellular Therapeutics
Immunovative Therapies
Insception Biosciences
Institute of Biomedical Research (Japan)
IntelliCell Biosciences
International Society for Stem Cell Research (ISSCR)
International Stem Cell Corporation (ISCO)
International Stemcell Services
Intrexon Corporation
Invivo Therapeutics
IPS Academia Japan
IRCCS San Raffaele Hospital
Israel Stem Cell Society
JCR Pharmaceuticals
Johann Wolfgang Goethe University Hospital
Johnson & Johnson
Karolinska Institute
Kreos Capital
Life Stem Genetics
Lifebank Cryogenics
LifebankUSA
LifeMap Sciences (subsidiary of BioTime)
LifeMap Solutions (owned by Lifemap Sciences)
LifeSouth Community Blood Centers
Lincoln Park Capital
Lonza
Massachusetts General Hospital
Maxcyte
Mayo Clinic
McLean Hospital
MedCell Bioscience
Medical Protective Company
Medicines and Healthcare Products Regulatory Agency (MHRA) (UK)
Medipost
Medistem (formerly Medistem Laboratories; acquired by Intrexon)
Medistem Panama
Medpace Inc.
Medtronic
Merck & Co.
Merck Millipore
Mesoblast
MetaCyte Business Lab
Miltenyi Biotec
Ministry of Economy, Trade and Industry (Japan)
Ministry of Food and Drug Safety (MFDS) (South Korea)
Ministry of Health (China)
Ministry of Science and Technology (China)
Monash University
Mount Sinai Hospital
Musculoskeletal Transplant Foundation
National Dental Pulp Laboratory (subsidiary of New England Cryogenic Center)
NeoStem
NeuralStem
NeuroGeneration
NeuroSearch
New England Cryogenic Center
New York Blood Center
New York Heart Association
Nippon Zoki Pharmaceutical
Northern Therapeutics
Novartis
NsGene
Nuo Therapeutics (formerly Cytomedix)
NuVasive
OncoCyte (subsidiary of BioTime)
Opexa Therapeutics
OrbusNeich
OrthoCyte (subsidiary of BioTime)
Orthofix
Osiris Therapeutics
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmicell (formerly FCB-Pharmicell)
Pharmsynthez
Plasticell
Pluristem
Polyphor
Proneuron Biotechnologies
Q Therapeutics
Queen Mary University of London
Quest Biomedical
Recyte Therapeutics (subsidiary of BioTime)
Regenerative Medicine Institute of Tijuana
Regenerative Sciences
Regenerex
Regenetech
Regeneus
Reliance Life Sciences
ReNeuron
Renovo Neural
RenovoCyte (subsidiary of Cook General BioTechnology)
RepliCel Life Sciences
ReproCELL
RhinoCyte
RIKEN Center for Developmental Biology
Roche
Roslin Cellab
RTI Surgical
RUSNANO
Rutgers University
Samuel Lunenfeld Research Institute
San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET)
SanBio
Saneron CCEL Therapeutics
Sanofi
Sao Paolo University Hospital
Schepens Eye Research Institute
S-Evans Biosciences
Singapore National Eye Centre
Sirna Therapeutics
Skye Orthobiologics
Society for Neuroscience
Spinesmith Partners
SSM Cardinal Glennon Children's Medical Center
St. Louis Cord Blood Bank
Stamina Foundation
Stem Cell Therapeutics
Stemcell Technologies
StemCells
StemCore
StemCyte
Stemedica Cell Technologies
StemGen
Stemina Biomarker Discovery
Stempeutics
SynBio (joint venture)
Takara Bio
TAP Biosystems (Sartorius Stedim Biotech)
Targazyme (formerly America Stem Cell)
Tel Aviv University
Teva
Texas Medical Board
Therapeutic Goods Administration (TGA) (Australia)
Theratechnologies
Tianhe Stem Cell Biotechnologies
TiGenix
Tong Yuan Stem Cell
TrakCel
Translational Biosciences (subsidiary of Medistem Panama)
UHV Technologies
UK Medical Research Council
uniQure
University College London
University of California San Francisco
University of Colorado
University of Heidelberg
University of Kyoto
University of Massachusetts
University of Miami
University of Milan
University of Minnesota
University of Washington
University of Wisconsin
Uppsala University Hospital
US Food and Drug Administration (FDA)
US National Institute of Allergy and Infectious Diseases (NIAID)
US National Institutes of Health (NIH)
US National Marrow Donor Program
US Patent and Trademark Office
Valeant
Vericel Corporation (formerly Aastrom Biosciences)
Vesta Therapeutics
ViaCord
ViaCyte (formerly NovoCell)
ViroMed Laboratories
Vitro Biopharma
WA Optimum Health Care
World Health Organization
Yale University
Yonsei University
Zhongyuan Union Stem Cell Bio-engineering
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain
Share this article